BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30333904)

  • 1. Genetic alterations associated with ALTered telomeres.
    Brosnan-Cashman JA; Graham MK; Heaphy CM
    Oncotarget; 2018 Sep; 9(73):33739-33740. PubMed ID: 30333904
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of a novel gene fusion in ALT positive osteosarcoma.
    Mason-Osann E; Dai A; Floro J; Lock YJ; Reiss M; Gali H; Matschulat A; Labadorf A; Flynn RL
    Oncotarget; 2018 Aug; 9(67):32868-32880. PubMed ID: 30214690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.
    de Wilde RF; Heaphy CM; Maitra A; Meeker AK; Edil BH; Wolfgang CL; Ellison TA; Schulick RD; Molenaar IQ; Valk GD; Vriens MR; Borel Rinkes IH; Offerhaus GJ; Hruban RH; Matsukuma KE
    Mod Pathol; 2012 Jul; 25(7):1033-9. PubMed ID: 22575867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
    Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
    Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.
    Liau JY; Lee JC; Tsai JH; Yang CY; Liu TL; Ke ZL; Hsu HH; Jeng YM
    Mod Pathol; 2015 Dec; 28(12):1545-54. PubMed ID: 26428317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas.
    Lee JC; Jeng YM; Liau JY; Tsai JH; Hsu HH; Yang CY
    Mod Pathol; 2015 Aug; 28(8):1064-73. PubMed ID: 26022452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.
    VandenBussche CJ; Allison DB; Graham MK; Charu V; Lennon AM; Wolfgang CL; Hruban RH; Heaphy CM
    Cancer Cytopathol; 2017 Jul; 125(7):544-551. PubMed ID: 28371511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas.
    Ahvenainen TV; Mäkinen NM; von Nandelstadh P; Vahteristo MEA; Pasanen AM; Bützow RC; Vahteristo PM
    Cancer; 2018 Dec; 124(24):4650-4656. PubMed ID: 30423196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features of ATRX or DAXX mutated neuroblastoma.
    Kurihara S; Hiyama E; Onitake Y; Yamaoka E; Hiyama K
    J Pediatr Surg; 2014 Dec; 49(12):1835-8. PubMed ID: 25487495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT).
    Falcinelli M; Dell'Omo G; Grassi E; Mariella E; Leto SM; Scardellato S; Lorenzato A; Arena S; Bertotti A; Trusolino L; Bardelli A; d'Adda di Fagagna F
    Cell Death Dis; 2023 Feb; 14(2):96. PubMed ID: 36759506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
    Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM
    Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587
    [No Abstract]   [Full Text] [Related]  

  • 12. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.
    Singhi AD; Liu TC; Roncaioli JL; Cao D; Zeh HJ; Zureikat AH; Tsung A; Marsh JW; Lee KK; Hogg ME; Bahary N; Brand RE; McGrath KM; Slivka A; Cressman KL; Fuhrer K; O'Sullivan RJ
    Clin Cancer Res; 2017 Jan; 23(2):600-609. PubMed ID: 27407094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.
    Hackeng WM; Brosens LAA; Kim JY; O'Sullivan R; Sung YN; Liu TC; Cao D; Heayn M; Brosnan-Cashman J; An S; Morsink FHM; Heidsma CM; Valk GD; Vriens MR; Nieveen van Dijkum E; Offerhaus GJA; Dreijerink KMA; Zeh H; Zureikat AH; Hogg M; Lee K; Geller D; Marsh JW; Paniccia A; Ongchin M; Pingpank JF; Bahary N; Aijazi M; Brand R; Chennat J; Das R; Fasanella KE; Khalid A; McGrath K; Sarkaria S; Singh H; Slivka A; Nalesnik M; Han X; Nikiforova MN; Lawlor RT; Mafficini A; Rusev B; Corbo V; Luchini C; Bersani S; Pea A; Cingarlini S; Landoni L; Salvia R; Milione M; Milella M; Scarpa A; Hong SM; Heaphy CM; Singhi AD
    Gut; 2022 May; 71(5):961-973. PubMed ID: 33849943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
    Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
    Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors.
    Mastrosimini MG; Manfrin E; Remo A; De Bellis M; Parisi A; Pedron S; Luchini C; Brunelli M; Ammendola S; Bernardoni L; Conti Bellocchi MC; Gabbrielli A; Facciorusso A; Pea A; Landoni L; Scarpa A; Crinò SF
    Pancreatology; 2023 Jun; 23(4):429-436. PubMed ID: 37169669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype.
    Amorim JP; Santos G; Vinagre J; Soares P
    Genes (Basel); 2016 Sep; 7(9):. PubMed ID: 27657132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATRX/DAXX: Guarding the Genome against the Hazards of ALT.
    Clatterbuck Soper SF; Meltzer PS
    Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological analysis of ATRX, DAXX and NOTCH receptor expression in angiosarcomas.
    Panse G; Chrisinger JS; Leung CH; Ingram DR; Khan S; Wani K; Lin H; Lazar AJ; Wang WL
    Histopathology; 2018 Jan; 72(2):239-247. PubMed ID: 28796347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomere length alterations and ATRX/DAXX loss in pituitary adenomas.
    Heaphy CM; Bi WL; Coy S; Davis C; Gallia GL; Santagata S; Rodriguez FJ
    Mod Pathol; 2020 Aug; 33(8):1475-1481. PubMed ID: 32203094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT Promoter Mutations but not the Alternative Lengthening of Telomeres Phenotype Are Present in a Subset of Ependymomas and Are Associated With Adult Onset and Progression to Ependymosarcoma.
    Brügger F; Dettmer MS; Neuenschwander M; Perren A; Marinoni I; Hewer E
    J Neuropathol Exp Neurol; 2017 Jan; 76(1):61-66. PubMed ID: 28040793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.